Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Simulations Plus Names Sharlene Evans to Board of Directors
Simulations Plus Names Sharlene Evans to Board of Directors


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it

Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Olderhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the

Dr. Otis Brawley Named to Agilent Board of Directors
Dr. Otis Brawley Named to Agilent Board of Directors


Agilent Technologies, Inc. (NYSE: A) today announced that Dr. Otis W. Brawley, a Bloomberg Distinguished Professor with the Department of Oncology and Epidemiology at the Johns Hopkins University

Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitishttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis


Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved XELJANZ® (tofacitinib) 5 mg twice daily for the treatment of adults with active ankylosing spondylitis (AS) who

Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it presented simulation

Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19


Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID™

Agilent Increases Cash Dividend to 21 Cents Per Share: https://unsplash.com/photos/WUehAgqO5hE
Agilent Increases Cash Dividend to 21 Cents Per Share


Agilent Technologies, Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 21 cents per share of common stock, reflecting an 8% increase over the previous quarter. The

Bronson Healthcare and Acadia Healthcare Break Ground on New Behavioral Health Hospital to Serve Southwest Michigan: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Bronson Healthcare and Acadia Healthcare Break Ground on New Behavioral Health Hospital to Serve Southwest Michigan


Bronson Healthcare and Acadia Healthcare Company today held a virtual groundbreaking ceremony marking the beginning of construction on the new hospital that the two companies are building together

Humana’s Preferred Medicare Part D Network to Include More Than 11,000 Retail Pharmacy Locations in 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana’s Preferred Medicare Part D Network to Include More Than 11,000 Retail Pharmacy Locations in 2022


Humana Inc. (NYSE: HUM), a leading health and well-being company, has announced that many of its Prescription Drug Plan (PDP) members will soon have even more low-cost and convenient options with

Pfizer Completes Acquisition of Trillium Therapeuticshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Completes Acquisition of Trillium Therapeutics


Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies for the

Waters’ 2021 Sustainability Report Highlights Progress on ESG Initiatives and Response to COVID-19
Waters’ 2021 Sustainability Report Highlights Progress on ESG Initiatives and Response to COVID-19


Waters Corporation (NYSE:WAT) today released its 2021 Sustainability Report, highlighting companywide achievements such as reductions in environmental impacts, supply chain enhancements and

Pfizer Announces Retirement of Chief Financial Officer Frank D’Ameliohttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio


Pfizer Inc. (NYSE: PFE) today announced that Frank D’Amelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer after a nearly 15 year

Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidatehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate


Pfizer Inc. today announced it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID™ (PF-07321332; ritonavir), for the treatment of mild to

New Report Finds Value-Based Care Agreements Benefited Humana Medicare Advantage Members with Reduced Hospitalizations, More Preventive Care During COVID-19 Pandemic: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
New Report Finds Value-Based Care Agreements Benefited Humana Medicare Advantage Members with Reduced Hospitalizations, More Preventive Care During COVID-19 Pandemic


Humana Inc. (NYSE: HUM) published its eighth annual Value-based Care (VBC) Report today, showing that Humana individual Medicare Advantage (MA) beneficiaries receiving care from primary care

AMN Healthcare Honored in the Top 3% of Public Corporate Boards for Gender Parity
AMN Healthcare Honored in the Top 3% of Public Corporate Boards for Gender Parity


AMN Healthcare has been honored by the Women’s Forum of New York as a national leader in female corporate board representation, achieving over 50% of Board of Directors’ seats held by women, among

Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services division

Charles River Laboratories to Participate in Upcoming Investor Conferences: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories to Participate in Upcoming Investor Conferences


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at two upcoming investor conferences, including:




  • Jefferies London Healthcare Conference

Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countrieshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries


Pfizer Inc. (NYSE: PFE) and the Medicines Patent Pool (MPP), a United Nations-backed public health organization working to increase access to life-saving medicines for low- and middle-income

PINC AI™ Applied Sciences (PAS) and Mölnlycke Health Care AB Clinical Trial Aims to Reduce Hospital-Acquired Infections (HAIs): https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
PINC AI™ Applied Sciences (PAS) and Mölnlycke Health Care AB Clinical Trial Aims to Reduce Hospital-Acquired Infections (HAIs)


The PINC AI™ Applied Sciences (PAS) team, a division of PINC AI, the technology and services platform of Premier, Inc. (NASDAQ: PINC), and Mölnlycke, a world-leading medical solutions company

Savara to Participate in Two Upcoming Investor Healthcare Conferences: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara to Participate in Two Upcoming Investor Healthcare Conferences


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the following healthcare

Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting


Novocure (NASDAQ: NVCR) today announced 31 presentations on Tumor Treating Fields (TTFields) will be featured at the Society for Neuro-Oncology (SNO) 2021 Annual Meeting from Nov. 18 to Nov. 21 in

2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma


Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight Brain Institute at the University of Florida, has released updated data from the

Pfizer Aktie: Impfung jetzt überflüssig?
Pfizer Aktie: Impfung jetzt überflüssig?
Die Wunderpille treibt die Pfizer Aktie auf ein neues 5-Jahreshoch. Doch was steckt genau hinter dem Medikament?
Savara Reports Third Quarter 2021 Financial Results and Provides Business Update: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Reports Third Quarter 2021 Financial Results and Provides Business Update


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the third quarter ending September 30, 2021 and